On October 17, 2024, Todd Harris, President and Chief Executive Officer of Tyra Biosciences Inc (TYRA, Financial), sold 58,726 shares of the company. The transaction was documented in an SEC Filing. Following this sale, the insider now owns 1,418,647 shares of Tyra Biosciences Inc.
Tyra Biosciences Inc is a biotechnology firm focused on developing precise therapies for patients with genetically defined diseases. The company's innovative platform and research are geared towards addressing significant needs in the treatment of cancer and other serious diseases.
The shares were sold at a price of $25.77, valuing the transaction at approximately $1,513,726.22. This sale is part of a broader trend observed over the past year, where the insider has sold a total of 187,280 shares and made no purchases. The company has seen a total of 13 insider sales and no insider buys during the same period.
The current market cap of Tyra Biosciences Inc stands at approximately $1.37 billion. The stock's valuation metrics, including the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, are accessible for further details on the company's financial health and stock valuation through the GF Value link.
The following insider trend image provides a visual representation of the recent insider transactions at Tyra Biosciences Inc:
This insider sale could be of interest to investors tracking insider behaviors as an indicator of company performance and future stock movement. However, it is essential to consider a broad range of financial and market factors when evaluating the potential impact of insider transactions on stock value.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
